HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Haemophilus influenzae type b infection — Clinical Guidelines

Overview

Haemophilus influenzae type b (Hib) infection primarily affects children under five years old, causing invasive diseases such as meningitis, pneumonia, and sepsis. Vaccination has significantly reduced the incidence of these severe infections 2.

Diagnosis

Clinical Presentation: Symptoms vary by site of infection (e.g., fever, lethargy, irritability for meningitis) 2.

Laboratory Tests: Blood cultures, cerebrospinal fluid (CSF) analysis for white cell count, protein levels, and Gram stain 2.

Serological Testing: Anti-polyribosylribitol phosphate (PRP) antibody levels to assess vaccine response 2.

Management

Antibiotic Therapy: Third-generation cephalosporins (e.g., ceftriaxone) for invasive infections 2.

Supportive Care: Focus on respiratory support, hydration, and management of complications like seizures 2.

Prophylactic Antibiotics: Considered in close contacts of index cases, though not routinely recommended for general prophylaxis 2.

Special Populations

Pediatrics: Primary target for Hib vaccination, typically administered at 2, 4, and 6 months with booster doses 2.

Comorbidities: No specific management adjustments noted in abstracts; standard care applies 2.

Key Recommendations

Vaccinate with Hib-containing vaccines to prevent invasive Hib disease in children 2 (Evidence: Strong).

Monitor anti-PRP antibody levels post-vaccination to ensure adequate immune response 2 (Evidence: Moderate).

Report adverse events following Hib vaccination through VAERS for surveillance and safety monitoring 3 (Evidence: Expert opinion).

References

1 Yin R, Liu C. Human coagulation factor IX: a systematic review of its characteristics. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2022. link 2 Wilck MB, Jin Xu Z, Stek JE, Goveia MG, Lee AW. Protective immune responses against Haemophilus influenza type b elicited by a fully-liquid DTaP-IPV-Hib-HepB vaccine (VAXELIS™). Vaccine 2021. link 3 Moro PL, Jankosky C, Menschik D, Lewis P, Duffy J, Stewart B et al.. Adverse events following Haemophilus influenzae type b vaccines in the Vaccine Adverse Event Reporting System, 1990-2013. The Journal of pediatrics 2015. link 4 Lozier JN. Gene therapy. Factor IX Padua: them that have, give. Blood 2012. link 5 Huang WT, Chang S, Miller ER, Woo EJ, Hoffmaster AR, Gee JE et al.. Safety assessment of recalled Haemophilus influenzae type b (Hib) conjugate vaccines--United States, 2007-2008. Pharmacoepidemiology and drug safety 2010. link 6 Holmberg L, Nilsson IM, Henriksson P, Orstavik KH. Homozygous expression of haemophilia B in a heterozygote. Acta medica Scandinavica 1978. link

Haemophilus influenzae type b infection